{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:40:12Z","timestamp":1791272412751,"version":"4.1.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T00:00:00Z","timestamp":1376956800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0070826","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T01:59:14Z","timestamp":1377050354000},"page":"e70826","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":95,"title":["Tumor Homogeneity between Primary and Metastatic Sites for BRAF Status in Metastatic Melanoma Determined by Immunohistochemical and Molecular Testing"],"prefix":"10.1371","volume":"8","author":[{"given":"Lucile","family":"Boursault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Vergier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cappellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Verdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bellocq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jouary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Merlio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,8,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1365-2133.2012.11125.x","article-title":"Melanoma incidence and mortality in Europe: new estimates, persistent disparities","volume":"167","author":"AM Forsea","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref2","unstructured":"GLOBOCAN 2008 (n.d.). Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/globocan.iarc.fr\/\" xlink:type=\"simple\">http:\/\/globocan.iarc.fr\/<\/ext-link>. Accessed 2013 Jan 20."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3322\/caac.21149","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"R Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"PB Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"MB Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"MR Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"JA Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"ref8","article-title":"NRAS and BRAF Mutations in Cutaneous Melanoma and the Association with MC1R Genotype: Findings from Spanish and Austrian Populations","author":"E Hacker","year":"2012","journal-title":"J Invest Dermatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma","volume":"29","author":"GV Long","year":"2011","journal-title":"JCO"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"H Davies","year":"2002","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of Mutated, Activated BRAF in Metastatic Melanoma","volume":"363","author":"KT Flaherty","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600\u2013Mutant Advanced Melanoma Treated with Vemurafenib","volume":"366","author":"JA Sosman","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CCO.0b013e3282f5271c","article-title":"The MAPK pathway in melanoma","volume":"20","author":"LA Fecher","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"PM Pollock","year":"2002","journal-title":"Nature Genetics"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1046\/j.1523-1747.2003.12559.x","article-title":"Mutations of the BRAF gene in benign and malignant melanocytic lesions","volume":"121","author":"AS Yazdi","year":"2003","journal-title":"J Invest Dermatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis","volume":"164","author":"J-H Lee","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma","volume":"367","author":"KT Flaherty","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"A Hauschild","year":"2012","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"GV Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref20","first-page":"391","article-title":"Dabrafenib and its potential for the treatment of metastatic melanoma","volume":"6","author":"AM Menzies","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1479-5876-8-67","article-title":"Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032","volume":"8","author":"J Rubinstein","year":"2010","journal-title":"Journal of Translational Medicine"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/2159-8290.CD-12-0097","article-title":"BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors","volume":"2","author":"KB Dahlman","year":"2012","journal-title":"Cancer Discovery"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"KT Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"ref24","article-title":"Detection of BRAF p.V600E Mutations in Melanomas: Comparison of Four Methods Argues for Sequential Use of Immunohistochemistry and Pyrosequencing","author":"E Colomba","year":"2012","journal-title":"J Mol Diagn"},{"key":"ref25","article-title":"Evaluation of BRAF Mutation Testing Methodologies in Formalin-Fixed Paraffin-Embedded Cutaneous Melanomas","author":"J Lade-Keller","journal-title":"The Journal of Molecular Diagnostics"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.sder.2012.07.007","article-title":"Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma","volume":"31","author":"JL Curry","year":"2012","journal-title":"Semin Cutan Med Surg"},{"key":"ref27","article-title":"Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma","author":"GV Long","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","article-title":"Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody","volume":"122","author":"D Capper","year":"2011","journal-title":"Acta Neuropathol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-011-0887-y","article-title":"Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases","volume":"123","author":"D Capper","year":"2012","journal-title":"Acta Neuropathol"},{"key":"ref30","article-title":"Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma","author":"JK Feller","year":"2012","journal-title":"Mod Pathol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jaad.2012.03.022","article-title":"Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1","volume":"67","author":"A Skorokhod","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/PAS.0b013e318271249e","article-title":"Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions","volume":"37","author":"KJ Busam","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"M Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e29336","DOI":"10.1371\/journal.pone.0029336","article-title":"Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma","volume":"7","author":"M Yancovitz","year":"2012","journal-title":"PLoS ONE"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0002-9440(10)61146-7","article-title":"A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization","volume":"160","author":"SF Paternoster","year":"2002","journal-title":"Am J Pathol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","volume":"364","author":"PB Chapman","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"ref37","article-title":"Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients","author":"M Ilie","year":"2012","journal-title":"Ann Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/bjc.2013.29","article-title":"BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma","volume":"108","author":"JS Wilmott","year":"2013","journal-title":"Br J Cancer"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/00313020801911512","article-title":"Detection of BRAF V600E mutation by pyrosequencing","volume":"40","author":"YH Tan","year":"2008","journal-title":"Pathology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2353\/jmoldx.2007.060191","article-title":"Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma","volume":"9","author":"C Spittle","year":"2007","journal-title":"J Mol Diagn"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jmoldx.2012.08.008","article-title":"Impact of mutation type and amplicon characteristics on genetic diversity measures generated using a high-resolution melting diversity assay","volume":"15","author":"MM Cousins","year":"2013","journal-title":"J Mol Diagn"},{"key":"ref42","article-title":"BRAF inhibitor activity in V600R metastatic melanoma","author":"O Klein","year":"2012","journal-title":"Eur J Cancer"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/2159-8290.CD-12-0097","article-title":"BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors","volume":"2","author":"KB Dahlman","year":"2012","journal-title":"Cancer Discovery"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.5858\/arpa.2011-0505-OA","article-title":"Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma","volume":"136","author":"S Anderson","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.bjc.6606072","article-title":"Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression","volume":"104","author":"J Lin","year":"2011","journal-title":"Br J Cancer"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/1078-0432.CCR-06-1820","article-title":"Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues","volume":"13","author":"J Jaeger","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref47","article-title":"BRAF mutation analysis of only one single metastatic lesion can restrict the treatment of melanoma - a case report","author":"E Richtig","year":"2012","journal-title":"British Journal of Dermatology: no\u2013no"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"R Nazarian","year":"2010","journal-title":"Nature"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"G Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"PI Poulikakos","year":"2011","journal-title":"Nature"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0070826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T21:05:41Z","timestamp":1588971941000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0070826"}},"subtitle":[],"editor":[{"given":"Roger","family":"Chammas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,20]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0070826","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,20]]}}}